Pacira BioSciences (FRA:82P) Inventories, Raw Materials & Components: €34.4 Mil (As of Mar. 2026)

Pacira BioSciences FRA:82P +2.75% 75 Inventories, Raw Materials & Components is €34.4 Mil as of Mar. 2026. GuruFocus rates FRA:82P with a GF Score™ of 75/100 and a GF Value™ of €25.72. The stock has 8 warning signs investors should review.

Pacira BioSciences's inventories, raw materials & components for the quarter that ended in Mar. 2026 was €34.4 Mil.

Pacira BioSciences's quarterly raw materials declined from Sep. 2025 (€39.6 Mil) to Dec. 2025 (€37.0 Mil) and declined from Dec. 2025 (€37.0 Mil) to Mar. 2026 (€34.4 Mil).

Pacira BioSciences's annual raw materials declined from Dec. 2023 (€49.6 Mil) to Dec. 2024 (€48.5 Mil) and declined from Dec. 2024 (€48.5 Mil) to Dec. 2025 (€37.0 Mil).

Pacira BioSciences Inventories, Raw Materials & Components Historical Data

* Premium members only.

The historical data trend for Pacira BioSciences's Inventories, Raw Materials & Components can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pacira BioSciences Inventories, Raw Materials & Components Chart

Pacira BioSciences Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

Inventories, Raw Materials & Components

Get a 7-Day Free Trial

32.16

37.58

49.61

48.51

37.01

Pacira BioSciences Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
Inventories, Raw Materials & Components	Get a 7-Day Free Trial															42.45	35.49	39.56	37.01	34.44

75GF Score

Pacira BioSciences Inc FRA:82P

Inventories, Raw Materials & Components is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Pacira BioSciences Inventories, Raw Materials & Components Calculation

Materials and components scheduled for use in making a product.

Frequently Asked Questions Learn more about Inventories, Raw Materials & Components →

What does a Inventories, Raw Materials & Components of €34.4 Mil mean?

Pacira BioSciences (FRA:82P) has a Inventories, Raw Materials & Components of €34.4 Mil as of Mar. 2026. Raw materials are the components a company uses for its main products. View historical data on Pacira BioSciences and its competitors.

Is Pacira BioSciences' Inventories, Raw Materials & Components too high?

Pacira BioSciences' current Inventories, Raw Materials & Components is €34.4 Mil. Overall, Pacira BioSciences has a GF Score™ of 75/100, reflecting its overall financial health beyond just this single metric.

How does Pacira BioSciences' Inventories, Raw Materials & Components compare to ETON and AMPH?

Pacira BioSciences' Inventories, Raw Materials & Components of €34.4 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Inventories, Raw Materials & Components for a Drug Manufacturers company?

A good Inventories, Raw Materials & Components depends on the Drug Manufacturers industry context. However, Inventories, Raw Materials & Components should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Inventories, Raw Materials & Components mean?

A high Inventories, Raw Materials & Components can signal that a stock is expensive relative to its fundamentals. Raw materials are the components a company uses for its main products. View historical data on Pacira BioSciences and its competitors. Pacira BioSciences's current Inventories, Raw Materials & Components is €34.4 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Pacira BioSciences stock overvalued right now?

Pacira BioSciences (FRA:82P) has a current Inventories, Raw Materials & Components of €34.4 Mil. The stock's GF Value™ is €25.72, compared to a current price of €22.40 — trading 12.9% below its estimated fair value. The current Inventories, Raw Materials & Components is €34.4 Mil. Pacira BioSciences' overall GF Score™ is 75/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Inventories, Raw Materials & Components calculated?

Inventories, Raw Materials & Components is calculated from a company's financial statements. For Pacira BioSciences (FRA:82P), the current Inventories, Raw Materials & Components is €34.4 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pacira BioSciences (FRA:82P) Overvalued in 2026?

Based on GuruFocus' analysis, Pacira BioSciences stock appears to be undervalued. The current stock price of €22.40 is trading 12.9% below its estimated GF Value™ of €25.72.

Key valuation signals for FRA:82P:

Inventories, Raw Materials & Components: €34.4 Mil
GF Value™: €25.72 vs. price of €22.40 (12.9% below fair value)
GF Score™: 75/100 with 8 warning signs

No single metric tells the full story. See the FRA:82P stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Pacira BioSciences Business Description

Industry Healthcare Drug Manufacturers

Comparable Companies ETON AMPH BIOA ESPR COLL ALVO PAHC IRWD XERS PRGO XTER:MRK XSWX:GALD TSE:4502 SHSE:600276 NSE:SUNPHARMA LSE:HLN XTAE:TEVA XSWX:SDZ ZTS UTHR

Other Exchanges PCRX:USA 82P:Germany

Address 2000 Sierra Point Parkway, Suite 900, Brisbane, CA, USA, 94005

Website https://www.pacira.com

Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.

75GF Score

Get the complete analysis for FRA:82P

Inventories, Raw Materials & Components is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€22.40

Price

€25.72

GF Value

View FRA:82P Analysis

See Inventories, Raw Materials & Components data for all stocks →